Prostate Cancer News and Research

Latest Prostate Cancer News and Research

Epigenomics concludes feasibility phase in development of improved product concept for Epi proColon

Epigenomics AG, the cancer molecular diagnostic company, today announced that it has concluded the feasibility phase in the development of an improved product concept for Epi proColon, the Company's DNA methylation-based blood test for assistance in the detection of individuals with colorectal cancer.

13 Jan 2011

MMRF, Synta collaborate for clinical development of ganetespib in multiple myeloma

The Multiple Myeloma Research Foundation (MMRF) today announced that it has entered into a joint collaboration with Synta Pharmaceuticals for the clinical development of ganetespib (formerly STA-9090) in patients with multiple myeloma.

13 Jan 2011

BIDMC scientist wins 2011 Pezcoller Foundation-AACR International Award for cancer research

Beth Israel Deaconess Medical Center cancer geneticist Pier Paolo Pandolfi, MD, PhD, is the recipient of the 2011 Pezcoller Foundation-AACR (American Association of Cancer Research) International Award for Cancer Research.

13 Jan 2011

Daiichi Sankyo and ArQule initiate enrollment in ARQ 197 Phase 3 trial in NSCLC

Daiichi Sankyo Company, Limited and ArQule, Inc. today announced that the first patient has been enrolled in the Phase 3 trial of ARQ 197, an investigational selective inhibitor of the c-Met receptor tyrosine kinase, in combination with erlotinib, for patients diagnosed with non-squamous, non-small cell lung cancer (NSCLC) who have received one or two prior systemic anti-cancer therapies.

12 Jan 2011

Insufficient evidence of interstitial brachytherapy's advantages for localized prostate cancer treatment

It remains an unresolved issue as to whether interstitial brachytherapy has advantages compared to other therapy options in men with localized prostate cancer, nor do newer studies provide proof in this respect. This is the result of a report published by the Institute for Quality and Efficiency in Health Care (IQWiG) on 11 January 2011.

12 Jan 2011

Negative aspects of prostate cancer screening acceptable

The negative aspects of screening for prostate cancer may be acceptable, since screening halves mortality from the disease. This is the conclusion of a thesis presented at the University of Gothenburg, Sweden.

12 Jan 2011

Study shows delivering cancer drug in hydrophobic nanoparticle is a safe and effective prostate cancer therapy

Researchers at MIT and Brigham and Women's Hospital have shown that they can deliver the cancer drug cisplatin much more effectively and safely in a form that has been encapsulated in a nanoparticle targeted to prostate tumor cells and is activated once it reaches its target.

12 Jan 2011

Behavioral therapies help improve bladder control in men following prostate cancer surgery

Behavioral therapies such as pelvic-floor-muscle training and bladder-control strategies can reduce incontinence episodes by more than 50 percent in men following prostate-cancer surgery, according to new research from the Center for Aging at the University of Alabama at Birmingham and the Birmingham/Atlanta Veterans Affairs Geriatric Research, Education and Clinical Center.

12 Jan 2011

Acne bacterium may also cause infections all over the body

A bacterium which causes acne and is commonly found on the skin, is now known to cause infections all over the body. Propionibacterium acnes (P. acnes)5 has been associated with infections of artificial joints and heart valves (endocarditis), as well as eye infections and chest infections - which are common at this time of year.

12 Jan 2011

BPH, hair loss prevention drugs may produce adverse side effects in men

Researchers from Boston University School of Medicine, in collaboration with colleagues at Lahey Clinic and from Denmark and Germany, have found that 5a-reductase inhibitors, while improving urinary symptoms in patients with benign prostatic hyperplasia and possible hair loss prevention, produces significant adverse effects in some individuals including loss of libido, erectile dysfunction, ejaculatory dysfunction and potential depression.

12 Jan 2011

Study to identify early warning biomarkers for presence of breast and prostate cancers

Using biological samples taken from patients and state-of-the-art biochemical techniques, a Florida State University researcher is working to identify a variety of "biomarkers" that might provide earlier warnings of the presence of breast and prostate cancers.

11 Jan 2011

VCU Massey Cancer Center introduces safer, more effective form of radiation therapy

Virginia Commonwealth University Massey Cancer Center has introduced a safer and more effective form of radiation therapy to treat cancer. The Center now offers volumetric modulated arc therapy (VMAT) delivery using the Philips Pinnacle3 SmartArc software to provide radiation treatment for multiple tumor sites, including prostate, head and neck, brain, breast and lung. VCU Massey is the first cancer center in the Richmond area to offer this cutting-edge radiation technique.

10 Jan 2011

Enzon to commence EZN-4176 Phase 1a/1b study in castration-resistant prostate cancer

Enzon Pharmaceuticals, Inc. today announced the Investigational New Drug (IND) approval by the US Food and Drug Administration (FDA) and plan to commence enrollment into a Phase 1a/1b study shortly. The study will evaluate the safety and tolerability of EZN-4176, the company's novel androgen receptor (AR) mRNA antagonist, for the treatment of patients with castration-resistant prostate cancer (CRPC).

10 Jan 2011

FDA grants Exelixis XL184 orphan drug designation for treatment of medullary thyroid cancer

Exelixis, Inc. today announced that the U.S. Food & Drug Administration (FDA) has granted orphan drug designation to XL184 for treatment of follicular, medullary, and anaplastic thyroid carcinoma, and metastatic or locally advanced papillary thyroid cancer. A pivotal phase 3 trial of XL184 is ongoing in patients with medullary thyroid cancer (MTC) and the company expects to release top-line phase 3 results in the first-half of 2011 and potentially file a New Drug Application (NDA) for the compound in the second-half of 2011.

10 Jan 2011

Dendreon provides U.S. commercialization and European strategy updates for PROVENGE

Dendreon Corporation today announced several updates regarding the U.S. commercialization of PROVENGE® (sipuleucel-T), the European strategy for PROVENGE, and progress on its pipeline.

7 Jan 2011

World's largest medical robotic conference

The International Robotic Urology Symposium 2011 is hosted by the Henry Ford Vattikuti Urology Institute and the Vattikuti Foundation.

7 Jan 2011

Elevated fat and cholesterol levels in diet may play a role in breast cancer development

Elevated fat and cholesterol levels found in a typical American-style diet play an important role in the growth and spread of breast cancer, say researchers at the Kimmel Cancer Center at Jefferson.

7 Jan 2011

NCCN Guidelines provide treatment information for patients with melanoma, prostate and ovarian cancer

People with melanoma, ovarian cancer, or prostate cancer now have a new resource that provides them with the same credible information their physicians use when determining treatment options. The National Comprehensive Cancer Network announces three new additions to the library of NCCN Guidelines for Patients, patient-friendly translations of the NCCN Clinical Practice Guidelines in Oncology.

6 Jan 2011

Physical activity associated with lower risk of death for prostate cancer patients: Study

A new study of men with prostate cancer finds that physical activity is associated with a lower risk of overall mortality and of death due to prostate cancer. The Harvard School of Public Health and University of California, San Francisco researchers also found that men who did more vigorous activity had the lowest risk of dying from the disease.

6 Jan 2011

EUSA receives FDA Priority Review status for ERWINAZE BLA

EUSA Pharma, a transatlantic specialty pharmaceutical company focused on oncology, oncology supportive care and critical care, today announced that its Biologics License Application for ERWINAZE(R) has been accepted for filing and awarded Priority Review status by the U.S. Food and Drug Administration.

5 Jan 2011

Prostate Cancer News and Research

Latest Prostate Cancer News and Research

Epigenomics concludes feasibility phase in development of improved product concept for Epi proColon

MMRF, Synta collaborate for clinical development of ganetespib in multiple myeloma

BIDMC scientist wins 2011 Pezcoller Foundation-AACR International Award for cancer research

Daiichi Sankyo and ArQule initiate enrollment in ARQ 197 Phase 3 trial in NSCLC

Insufficient evidence of interstitial brachytherapy's advantages for localized prostate cancer treatment

Negative aspects of prostate cancer screening acceptable

Study shows delivering cancer drug in hydrophobic nanoparticle is a safe and effective prostate cancer therapy

Behavioral therapies help improve bladder control in men following prostate cancer surgery

Acne bacterium may also cause infections all over the body

BPH, hair loss prevention drugs may produce adverse side effects in men

Study to identify early warning biomarkers for presence of breast and prostate cancers

VCU Massey Cancer Center introduces safer, more effective form of radiation therapy

Enzon to commence EZN-4176 Phase 1a/1b study in castration-resistant prostate cancer

FDA grants Exelixis XL184 orphan drug designation for treatment of medullary thyroid cancer

Dendreon provides U.S. commercialization and European strategy updates for PROVENGE

World's largest medical robotic conference

Elevated fat and cholesterol levels in diet may play a role in breast cancer development

NCCN Guidelines provide treatment information for patients with melanoma, prostate and ovarian cancer

Physical activity associated with lower risk of death for prostate cancer patients: Study

EUSA receives FDA Priority Review status for ERWINAZE BLA

What to know about prostate cancer eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Prostate Cancer News and Research

Latest Prostate Cancer News and Research

What to know about prostate cancer eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in